RxDoctor Payments Data

Kurt Klussmann, MD

Ophthalmology · Silverdale, WANPI 1427005040

Payments from drug & device makers

$788in general payments, 2019–2025

Across 22 payments — averaging $35.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$445
  • Sun Pharmaceutical Industries Inc.$118
  • AbbVie$87
  • Tarsus Pharmaceuticals, Inc.$47
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$31
  • Kala Pharmaceuticals, Inc.$21
  • plus $38 from 2 others

What the payments were for

  • Food & beverage$76898%
  • Gifts$192%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$788 in reported general payments places this provider in the 45th percentile of 428 ophthalmology providers in Washington.

See all ophthalmology providers in Washington

Medicare billing

Part B allowed, 2024
$410,678
Medicare patients
1,290
Services billed
3,765

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine71$91,353
LumiganBimatoprost44$27,325
ProlensaBromfenac Sodium70$24,079
BesivanceBesifloxacin Hcl75$16,593
Cyclosporine20$11,088
RocklatanNetarsudil Mesylat/Latanoprost12$9,833
Travoprost29$7,144
Latanoprost405$6,704
Difluprednate63$6,469
Brinzolamide26$4,312
Timolol Maleate237$3,602
Dorzolamide-TimololDorzolamide/Timolol/Pf14$2,594
TafluprostTafluprost/Pf12$1,805
ErythromycinErythromycin Base52$527
Dorzolamide Hcl16$369

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$87$118,678115 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Besivance$31$40,672145 claims
Aerie Pharmaceuticals, Inc.Rocklatan$19$9,83312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 428 ophthalmology providers in Washington.

Other ophthalmology in Silverdale

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →